LENZ Therapeutics (LENZ) Change in Account Payables (2020 - 2026)
LENZ Therapeutics (LENZ) reported Change in Account Payables of $6.8 million for Q1 2026, up 977.04% year-over-year from $627830.2 in Q1 2025, and up 4434.62% on a QoQ basis from -$156000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Change in Account Payables data on file, last reported at $6.8 million in Q1 2026.
- Quarterly Change in Account Payables rose 977.04% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (up 296.85% YoY) and the FY2025 annual result came in at -$90000.0, up 97.9% from the prior year.
- Change in Account Payables grew to $6.8 million in Q1 2026 per LENZ's latest filing, from -$156000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.8 million in Q1 2026 and bottomed at -$2.7 million in Q2 2024.
- The 5-year median for Change in Account Payables is -$156000.0 (2025), against an average of $202529.4.
- The widest annual swing landed in 2023, when Change in Account Payables sank 642.86%; it then surged 977.04% in 2026.
- Tracing LENZ's Change in Account Payables over 5 years: stood at -$1.1 million in 2022, then jumped by 200.65% to $1.1 million in 2023, then grew by 21.32% to $1.3 million in 2024, then tumbled by 111.82% to -$156000.0 in 2025, then surged by 4434.62% to $6.8 million in 2026.
- Per Business Quant, the three latest LENZ Change in Account Payables figures stand at $6.8 million (Q1 2026), -$156000.0 (Q4 2025), and $1.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 6.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.76 Mn |
| Mar 31, 2026 | 6.76 Mn |
| Dec 31, 2025 | -156,000.00 |
| Dec 31, 2025 | -156,000.00 |
| Sep 30, 2025 | 1.69 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | -857,000.00 |
| Jun 30, 2025 | -857,000.00 |
| Mar 31, 2025 | -771,000.00 |
| Mar 31, 2025 | -771,000.00 |
| Dec 31, 2024 | 1.32 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | -1.64 Mn |
| Sep 30, 2024 | -1.64 Mn |
| Jun 30, 2024 | -2.69 Mn |
| Jun 30, 2024 | -2.69 Mn |
| Mar 31, 2024 | -1.27 Mn |
| Mar 31, 2024 | -1.27 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | -1.63 Mn |
| Jun 30, 2023 | -1.63 Mn |
| Mar 31, 2023 | -567,000.00 |
| Mar 31, 2023 | -567,000.00 |
| Dec 31, 2022 | -1.08 Mn |
| Dec 31, 2022 | -1.08 Mn |
| Sep 30, 2022 | 392,000.00 |
| Sep 30, 2022 | 392,000.00 |
| Jun 30, 2022 | 301,000.00 |
| Jun 30, 2022 | 301,000.00 |
| Mar 31, 2022 | 582,000.00 |
| Mar 31, 2022 | 582,000.00 |
| Dec 31, 2021 | 710,000.00 |
| Dec 31, 2021 | 710,000.00 |
| Sep 30, 2021 | -2.34 Mn |
| Sep 30, 2021 | -2.34 Mn |
| Jun 30, 2021 | 3.37 Mn |
| Jun 30, 2021 | 3.37 Mn |
| Mar 31, 2021 | 83,000.00 |
| Mar 31, 2021 | 83,000.00 |
| Dec 31, 2020 | 201,000.00 |
| Dec 31, 2020 | 201,000.00 |
| Sep 30, 2020 | 113,000.00 |
| Sep 30, 2020 | 113,000.00 |